<DOC>
	<DOCNO>NCT01958671</DOCNO>
	<brief_summary>This trial evaluate efficacy safety ertugliflozin monotherapy treatment subject type 2 diabetes mellitus ( T2DM ) inadequate glycemic control diet exercise . This trial consist run-in period 3 11 week , 26-week placebo-controlled treatment period ( Phase A ) , 26-week active treatment period ( Phase B ) . The primary hypothesis trial Week 26 , mean reduction baseline hemoglobin A1c ( HbA1c ) 15 mg ertugliflozin great placebo .</brief_summary>
	<brief_title>A Study Efficacy Safety Ertugliflozin Monotherapy Treatment Participants With Type 2 Diabetes Mellitus Inadequate Glycemic Control Despite Diet Exercise ( MK-8835-003 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Diagnosis T2DM accordance American Diabetes Association guideline Participants prior allowable oral antihyperglycemic agent ( AHA ) least 8 week prior study participation participant single allowable oral AHA start study participation Particpants single allowable AHA must willing discontinue medication Screening Visit ( S2 ) remain medication duration trial . Allowable oral AHAs discontinuation metformin , sulfonylurea , dipeptidyl peptidase4 ( DPP4 ) inhibitor , glinides alphaglucosidase inhibitor . History myocardial infarction , unstable angina , arterial revascularization , stroke , transient ischemic attack , New York Heart Association ( NYHA ) functional class IIIIV heart failure within 3 month study participation A clinically significant electrocardiogram abnormality A history malignancy â‰¤5 year prior study participation , except adequately treat basal squamous cell skin cancer situ cervical cancer A know hypersensitivity intolerance sodiumglucose cotransporter 2 ( SGLT2 ) inhibitor metformin On blood pressure lipid alter medication stable dose least 4 week prior study participation A surgical procedure within 4 week prior study participation plan major surgery trial Donation blood blood product within 6 week study participation plan donate blood blood product time trial Pregnant breastfeeding , expect conceive trial , include 14 day follow last dose study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>